Implications of prostate-specific antigen screening guidelines on clinical practice at a Canadian regional community hospital

Webster, Todd M.; Lau, Erika; Newell, Ken J.

doi:10.5489/cuaj.4140

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Men aged 40 years or older with a family history of prostate cancer, • Men racially at risk of prostate cancer, such as African-Canadians, • Men aged 50 to 75 years old (who have a life expectancy of at least 10 years or more, however, Ontario guidelines do not recommended PSA screening for men over 75 years) and, • Men at any age who have a physician willing to screen him, but must pay a fee (Webster, Lau, & Newell, 2017).…”

Section: Author Notementioning

confidence: 99%

Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012

Watson¹

2020

CONJ

View full text Add to dashboard Cite

Objectives: This study investigates change in prostate-specific antigen (PSA) screening uptake in Ontario among men 35 years of age and older, between 2003 and 2012. We identify factors related to PSA testing, and examine the degree to which age guidelines for PSA testing are being followed or if PSA screening is opportunistic in nature. The relationship of income, education and having a regular physician and an estimation of PSA testing prevalence in 2012 is also studied. Methods: Data from the Canadian Community Health Survey (CCHS) were used to estimate the proportion of men who had a PSA test in 2003 and then compared to a similar estimate (in similar population) in 2012. We also examined associations with PSA uptake to socio-demographic factors. Contingency table analyses were performed to characterize the changes; logistic regression was also used to evaluate the differences, while taking into account the possible confounding role of other factors. Results: We found among men aged 35-49 years and 75+, there was an increase in PSA utilization between 2003 and 2012. In 2003, 18% of men 35-49 years, and 74% of men aged 75+ reported ever having a PSA test. These figures increased to 20% of men aged 35-49 years, and 84% of men aged 75+ years in 2012. Logistic regression showed that a man in the 70-74 age category in 2012 had the highest likelihood of having had a PSA test compared to men in the age range of 35-49 years (odds ratio (OR)=25.9; confidence interval (CI)= 19.9-33.8). Conclusion: In Ontario, PSA testing is seemingly opportunistic in nature and occurring in groups not recommended for testing by the Ontario guidelines. There is a marked increase in PSA utilization in age ranges outside of the current Ontario PSA testing guidelines (35-49 and 75+). It would appear that most PSA testing in Ontario is opportunistic and adherence to age guidelines is limited.

show abstract

Section: Author Notementioning

confidence: 99%

Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012

Watson¹

2020

CONJ

View full text Add to dashboard Cite

show abstract

“…Webster et al, in a recent issue of CUAJ, nicely illustrates one region's experiences on PSA use and its impact of early diagnosis in a relatively captured/stable market in Ontario. 4 Several observational and modelling studies have quantified something we all seem to have witnessed over the last few years: decreased incidence of prostate cancer with a subsequent stage migration and PSA screening: Time to overcome our brand confusion EDITORIAL more metastatic disease in our clinics. In a recent turnabout this spring, the USPSTF has subsequently issued a new draft revision for prostate cancer screening upgrading its recommendation back to a C, encouraging physicians to discuss with their patients whether or not early prostate cancer detection is appropriate for them.…”

mentioning

confidence: 99%

PSA screening: Time to overcome our brand confusion

Gleave

2017

CUAJ

View full text Add to dashboard Cite

Changements dans les pratiques de dépistage de l’antigène prostatique spécifique en Ontario entre 2003 et 2012

Watson¹

2020

CONJ

View full text Add to dashboard Cite

show abstract

Implications of prostate-specific antigen screening guidelines on clinical practice at a Canadian regional community hospital

Cited by 3 publications

References 15 publications

Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012

Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012

PSA screening: Time to overcome our brand confusion

Changements dans les pratiques de dépistage de l’antigène prostatique spécifique en Ontario entre 2003 et 2012

Contact Info

Product

Resources

About